Business
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MEI Pharma, Inc. - MEIP
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MEI Ph...
About this update from Lithos Group Ltd
[{"type":"text","content":"\n\n\n\nSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MEI Pharma, Inc. - MEIP\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nNEW YORK, July 2, 2020\n\n\n\nNEW YORK, July 2, 2020 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of MEI Pharma, Inc. (\"MEI Pharma\" or the \"Company\") (NASDAQ: MEIP).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.\nThe investigation concerns whether MEI Pharma and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  \n[Click here for information about joining the class action] \nOn July 2, 2020, MEI Pharma announced that it was discontinuing its Phase 3 study of Pracinostat, an oral histone deacetylase inhibitor being investigated in combination with azacitidine for the treatment of adults with newly diagnosed acute myeloid leukemia who are unfit for standard intensive chemotherapy.  Specifically, the Company advised that an interim futility analysis of the ongoing Phase 3 study, undertaken by the study's Independent Data Monitoring Committee, \"has demonstrated it was unlikely to meet the primary endpoint of overall survival compared to the control group,\" and that \"[b]ased on the outcome of the interim analysis, the decision was made to discontinue the recruitment of patients and end the study,\" which \"was based on a lack of efficacy and not on safety concerns.\"  \nFollowing MEI Pharma's announcement, the Company's stock price fell $0.78 per share, or 18.27%, to close at $3.49 per share on July 2, 2020.\nThe Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years la...